Bavarian Nordic to Present at Jefferies 2014 Global Healthcare Conference in New York

KVISTGAARD, Denmark - June 4, 2014 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) announced today that Ole Larsen, Executive Vice President & CFO will present at the Jefferies 2014 Global Healthcare Conference in New York on Thursday, June 5, 2014 at 9:00 AM EDT.

A live and archived webcast of the presentation can be accessed through the Company's website www.bavarian-nordic.com under "Investor & Media > Events".

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on Nasdaq OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com.

Contacts
U.S.: Seth Lewis, Vice President, Investor Relations. Phone: + 1 978-298-5654
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43